Findings
========

Background
----------

The plaque reduction neutralization test (PRNT) is a method for measuring antibodies that neutralize and prevent virions from infecting cultured cells. It is currently the most virus-specific serological test among the flaviviruses, and serotype-specific test among the dengue viruses \[[@B1]\]. PRNT has been widely used in assessing the protective neutralizing antibody response for Japanese-encephalitis vaccines \[[@B2]-[@B4]\].

For dengue, PRNT is the best and most widely accepted approach to measuring virus-neutralizing and protective antibodies \[[@B1]\], and assessing the immunogenicity of dengue vaccine \[[@B5]-[@B8]\]. However, the correlation between the presence of virus-neutralizing antibody and protection from infection is not absolute. This report aims to provide additional data on the correlation of pre-existing dengue-neutralizing antibody and protection from subsequent dengue infection.

Methods
=======

In the cohort study conducted among school children in Ratchaburi Province, Thailand \[[@B9]\], we prospectively collected serum samples annually from all subjects. Acute and convalescent serum samples were also collected from each febrile subject, irrespective of clinical diagnosis. Clinical diagnosis was performed by a pediatrician who was unaware of the dengue diagnostic test results. Clinical diagnoses of dengue fever (DF), dengue hemorrhagic fever (DHF), and DHF severity were made using the WHO criteria (1997) \[[@B10]\]. All blood samples were drawn into serum separator tubes, allowed to clot at room temperature for 1--2 hours, then stored at 4°C. Sera were separated into aliquots within 24 hours and stored at −70°C until laboratory testing. Dengue diagnostic testing was performed at the Center for Vaccine Development, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakhonpathom, Thailand (CVD). Acute and convalescent sera were tested for dengue-virus-specific IgM/IgG by enzyme-linked immunosorbent assay (ELISA) using slightly modified method from that described previously \[[@B11]\]. The sensitivity of this test was 97% in paired sera \[[@B11]\]. An IgM anti-dengue level ≥ 1 unit in acute serum, or seroconversion of either IgM or IgG in paired sera, was considered indicative of acute dengue infection. Primary dengue infection was diagnosed when the IgM:IgG ratio was \>1:1.8. Serum samples from acute dengue cases were tested for dengue-virus serotype by inoculation into *Toxorhynchites splendens* mosquitoes with immunofluorescence detection and serotyping \[[@B12]\].

We randomly selected 48 subjects with acute dengue infection in the year 2006. Pre-infection sera were retrieved from the previous annual serum samples and tested for pre-existing dengue- and Japanese encephalitis-neutralizing antibody using PRNT, as described by Russell *et al.*\[[@B13]\]. In the tests, conducted at the CVD, monkey kidney-derived LLC-MK2 cells were used for virus production and PRNT. The dengue viruses (D) used in the assay were D1 (16007), D2 (16681), D3 (16562), and D4 (1036). LLC-MK2 cells were seeded in 6-well plates at 1 × 10^5^ cells/well, and incubated for 6--8 days. Neutralizing sera were diluted to 1:5, followed by ten-fold serial dilutions using phosphate buffer solution (PBS) pH 7.5 with 30% fetal bovine serum, mixed with virus (for a final starting dilution of 1:10), and incubated. Following infection, cells were overlaid with 3.0% carboxymethyl cellulose with neutral red added. Plaques were visualized and counted after cultivation for 7 days. Data were interpreted using the Probit model with the SPSS program, and PRNT endpoint titers were expressed as the reciprocal of the last serum dilution. The PRNT titer was calculated based on a 50% reduction in plaque count (PRNT50).

Results
=======

Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"} show the pre-existing dengue PRNT50 titers in the sera of subjects in February 2006, date of subsequent dengue illness, clinical diagnosis, and the serotype isolated. Among 48 subjects with serologically confirmed dengue infection, dengue viruses could be identified in 31 (64.6%) subjects, comprising 16 D1; 1 D2; 3 D3; and 11 D4. Only 5 (10.4%) subjects had primary infections.

###### 

Pre-existing PRNT50 titer and subsequent dengue infection in subjects with low titer (\<90) to subsequent infecting serotype

   **Subject code**   **PRNT50 titer (Feb 2006)**   **Date of illness**   **Clinical diagnosis**   **ELISA test result**^**a**^   **Serotype isolated**                                         
  ------------------ ----------------------------- --------------------- ------------------------ ------------------------------ ----------------------- ------------ ------------- ----------- ----
        03-146                   \<10                      \<10                    \<10                        \<10                        155            11/10/2006       DF        Secondary   D1
        05-119                   \<10                      \<10                    \<10                        \<10                        235             9/6/2006    Pharyngitis   Secondary   D1
        05-181                   \<10                      \<10                    \<10                        \<10                       \<10            21/8/2006        DF         Primary    D1
        05-310                    10                       \<10                    167                         \<10                        250            21/4/2006        DF        Secondary   D1
        07-479                   \<10                      \<10                    \<10                        \<10                        29             23/7/2006        DF        Secondary   D1
        07-383                    13                       \<10                    \<10                        \<10                       \<10            10/9/2006        DF         Primary    D1
        04-276                    13                       \<10                    \<10                        \<10                       \<10            13/3/2006        DF         Primary    D1
        05-357                    40                        29                      27                         \<10                        303            10/10/2006   Bronchitis    Secondary   D1
        05-002                    50                       \<10                    \<10                        \<10                        396            25/11/2006       DF        Secondary   D1
        03-097                    75                       1134                     24                          20                        1307            7/10/2006        DF        Secondary   D1
        05-339                   \<10                      \<10                    \<10                        \<10                        503            28/8/2006    Pharyngitis   Secondary   D2
        04-322                    17                       \<10                    \<10                        \<10                        165            9/11/2006        DF        Secondary   D3
        04-325                   \<10                      \<10                    \<10                        \<10                        685            23/10/2006     DHF gr2     Secondary   D3
        02-189                   \<10                       10                      12                         \<10                       \<10             6/7/2006        DF         Primary    D3
        01-227                    49                       \<10                    \<10                        \<10                        590            19/2/2006    Pharyngitis   Secondary   D4
        01-254                   12450                     3348                     32                         \<10                        78             28/2/2006        AGE       Secondary   D4
        01-384                   \<10                      \<10                    \<10                        \<10                        92             19/12/2006   Pharyngitis   Secondary   D4
        06-164                    210                       540                   12040                         21                         76             30/8/2006        DF        Secondary   D4
        01-124                    228                       135                    516                          39                         28             31/3/2006        DF        Secondary   D4
        05-257                   3141                       194                    272                          41                         726            15/10/2006   Common cold   Secondary   D4
        01-224                    195                      2901                    220                          50                         802             9/3/2006      DHF gr1     Secondary   D4
        05-378                   6238                      2204                    676                          75                         43             28/7/2006        DF        Secondary   D4

^a^ELISA result showed either primary or secondary infection.

AGE: acute gastroenteritis; D: dengue virus; DF: dengue fever; DHF: dengue hemorrhagic fever; gr: grade; JE: Japanese encephalitis virus; PRNT50: 50% plaque reduction neutralization.

###### 

Pre-existing PRNT50 titer and subsequent dengue infection in subjects with high titer (\>90) to subsequent infecting serotype

   **Subject code**   **PRNT50 titer (Feb 2006)**   **Date of illness**   **Clinical diagnosis**   **ELISA test result**^**a**^   **Serotype isolated**                                            
  ------------------ ----------------------------- --------------------- ------------------------ ------------------------------ ----------------------- ----------- ----------------- ----------- ----
        06-043                    121                       224                     83                         \<10                        11             14/8/2006         DF          Secondary   D1
        05-021                    133                      \<10                    \<10                        \<10                        72             26/4/2006         DF          Secondary   D1
        05-074                    173                      1136                     73                          31                         503            9/5/2006          DF          Secondary   D1
        06-082                    317                      \<10                     18                         \<10                        760            14/6/2006   Viral infection   Secondary   D1
        01-286                    581                      \<10                    \<10                        \<10                       \<10            19/4/2006         DF          Secondary   D1
        01-141                   1848                       821                    4521                        328                         738            6/11/2006     Pharyngitis     Secondary   D1
        07-119                   5291                       84                     332                          98                         207            28/7/2006         DF          Secondary   D4
        05-244                   4916                      1305                    1006                        145                         393            21/9/2006         DF          Secondary   D4
        04-378                   11682                      853                    417                         261                        5615            5/7/2006          DF          Secondary   D4

^a^ELISA result showed either primary or secondary infection.

D: dengue virus; DF: dengue fever; JE: Japanese encephalitis virus; PRNT50: 50% plaque reduction neutralization.

###### 

Pre-existing PRNT50 titer and subsequent dengue infection among subjects whose subsequent infecting serotypes could not be identified

   **Subject code**   **PRNT50 titer (Feb 2006)**   **Date of illness**   **Clinical diagnosis**   **ELISA test result**^**a**^                                         
  ------------------ ----------------------------- --------------------- ------------------------ ------------------------------ ------- ------------ ----------------- -----------
        01-177                    537                       218                    619                          74                 14      1/6/2006      Pharyngitis     Secondary
        01-437                    473                       297                    1283                        \<10                75      9/9/2006       Influenza      Secondary
        01-456                   14105                     2851                    7872                        235                 594    27/6/2006          DF          Secondary
        01-559                    393                      1606                    249                          65                4987    14/8/2006    viral infection   Secondary
        02-246                   \<10                      \<10                     16                         \<10               2201     3/5/2006          DF          Secondary
        02-434                   \<10                      \<10                    \<10                        \<10               1326    31/3/2006      Pharyngitis     Secondary
        02-453                    172                      2053                    126                          53                14587   10/3/2006        DHF gr3       Secondary
        03-021                    867                      \<10                    1026                        \<10               \<10    29/11/2006       DHF gr1       Secondary
        05-072                    351                       36                     \<10                        174                 140    1/12/2006    Viral infection   Secondary
       05-0112                   \<10                      \<10                    \<10                        \<10               \<10    2/12/2006          URI          Primary
        05-209                    310                       48                     753                          14                 76     29/7/2006        DHF gr1       Secondary
        05-239                   3257                      8199                    111                          40                 919    24/4/2006        DHF gr1       Secondary
        05-358                    249                       247                    3934                         34                 267    10/6/2006    Viral infection   Secondary
        06-070                    236                      2687                   10649                        \<10                94     16/6/2006      Pharyngitis     Secondary
        06-124                    472                      5074                    3943                         29                 164    27/8/2006        DHF gr1       Secondary
        06-192                    10                       \<10                    \<10                        \<10                42     26/8/2006      Pharyngitis     Secondary
        07-310                    137                       43                      23                         198                 21      7/8/2006       Influenza      Secondary

^a^The ELISA result showed either primary or secondary infection.

D: dengue virus; DF: dengue fever; DHF: dengue hemorrhagic fever; gr: grade; JE: Japanese encephalitis virus; PRNT50: 50% plaque reduction neutralization.

Of 31 subjects whose infecting dengue serotypes were identified, 14 (45.2%) had pre-existing PRNT50 titers to the infecting serotype \< 20. Eight subjects (25.8%) had pre-existing PRNT50 titers to the infecting serotype of between 21 and 75 (Table [1](#T1){ref-type="table"}).

Interestingly, nine (29.0%) subjects had pre-existing PRNT50 titers of \> 90 to the subsequent infecting serotypes. Six subjects with D1 infections had pre-existing PRNT50 titers to D1, which ranged from 121 to 1848; geometric mean value 313; median value 245. Two subjects (subjects 01--286 and 05--021) had PRNT50 profiles suggesting previous primary D1 infection, but had secondary symptomatic infections with the same serotype. Three subjects with D4 infections had pre-existing PRNT50 titers to D4, ranging between 98 to 261, geometric mean value 154 (Table [2](#T2){ref-type="table"}).

It is worth noting that many subjects (e.g. subjects 01--456 and 04--378) had pre-existing PRNT50 profiles suggesting secondary dengue infection, but still had symptomatic infections, which were probably tertiary infections (Tables [3](#T3){ref-type="table"} and [2](#T2){ref-type="table"}, respectively).

Discussion
==========

Dengue viruses comprise 4 serotypes. Infection with one dengue serotype elicits lifelong homotypic immunity, but only short-lived immunity for heterotypic serotypes \[[@B14]\]. Dengue neutralizing antibody has been believed to represent protection against dengue, and the PRNT test has been widely used to measure this neutralizing antibody. Numerous vaccine immunogenicity assessment laboratories consider a seropositive threshold to be 10 \[[@B1]\] and since four of the subjects in this report had PRNT50 titers of 10--13, we arbitrarily divided the subjects into 3 groups, i.e. titer \<20, 20--90, and \>90. We found that 17 (54.8%) and 9 (29.0%) of 31 subjects had pre-existing PRNT50 titers \>20 and \>90, respectively, to the subsequent infecting dengue serotype. These data provide partial insight into the correlation between PRNT50 titer and disease protection. This is very important, because PRNT titer is considered an important marker of protection in the development of dengue vaccines. These data are perhaps the most relevant available data, as more valid data on the correlation between pre-existing PRNT50 titer and disease protection in humans requires human challenge with dengue virus, which may not be possible due to ethical issues. This report raises some inconsistencies with our previous understandings. First, the finding in 2 subjects (subjects 01--286 and 05--021 \[Table [2](#T2){ref-type="table"}\]) suggests that previous D1 infection may not induce protection to subsequent symptomatic homotypic dengue infection. Second, a quite high pre-existing PRNT50 titer (\>90) may not be able to protect against subsequent symptomatic infection from the respective dengue serotype.

In a cohort study in Thailand, Endy *et al*. \[[@B15]\] also found that pre-existing neutralizing antibody directed against infecting dengue serotype (titer \>10) was detected in 36%, 67%, and 46% of D3, D2, and D1 infections, respectively. Moreover, only a pre-existing PRNT50 \> 100 against the reference D3 strain was associated with milder severity of disease, but not in D2 and D1. This is further confirmed by the finding in a phase-2b dengue-vaccine trial among Thai children that the tetravalent live-attenuated dengue vaccine had a low level of efficacy against D2, despite its high immunogenicity \[[@B16]\].

There are some possible explanations for the lack of a definite correlation between PRNT50 titer and protection from subsequent dengue infection. One possible explanation is that in our PRNT, we used LLC-MK2 cells, which are not FcγR-expressing cells. In the absence of FcγR, dengue virus-antibody complexes are not able to infect the cells, while these complexes are taken up more efficiently by FcγR-expressing cells, and are still infectious \[[@B17]\]. This is supported by the study of Moi *et al.*\[[@B18]\], who found that 11 of 18 serum samples from patients with acute secondary dengue infection demonstrated neutralizing activity to the infecting serotype, determined using FcγR-negative BHK cells, but not when determined using FcγR-expressing cells. Another explanation is that the protective PRNT50 titer for dengue may be much higher than the titer of 10, defined for Japanese encephalitis virus, and the protective level of dengue neutralizing antibody should be more accurately defined. This study revealed that subjects with pre-existing PRNT50 titer of up to 1848 against D1, and 261 against D4, still had symptomatic infections due to the respective serotypes, suggesting the protective level should be higher and may differ for different serotypes. Nevertheless, defining the protective-level cut-off point is difficult and challenging. A very large cohort study and long-term follow-up are needed, unless a challenge test in subjects with pre-defined PRNT levels could be conducted. Moreover, as PRNT titers vary significantly depending on testing conditions, such as virus strains, virus passage and cell type \[[@B19],[@B20]\], optimal testing conditions should be defined.

Finally, the pre-infection PRNT50 titers are against reference dengue-virus strains. As molecular evolution among dengue viruses has been continuous \[[@B21]\], it may cause antigenic mismatches between the reference dengue virus strains used in the PRNT and infecting viruses, and therefore, mismatch between the pre-existing antibody and the antigen of the infecting homologous serotype. Further studies are needed to clarify these possibilities.

It is also noted that dengue-naïve but Japanese encephalitis (JE)-immuned subjects shown by PRNT (e.g. subjects 01--384, 04--325, 07--479) showed secondary antibody response to subsequent dengue infection. One subject (subject 04--325) had DHF grade2. These pieces of evidence suggest cross-reactive antibody responses between dengue and JE.
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